Houston startup completes testing, prepares biosimilar insulin drug for clinical trials

next steps

A Houston-based biotech company has completed early testing for its groundbreaking insulin alternative and is headed toward clinical trials. Photo via Getty Images

A Houston biotech startup is one step closer to releasing its marquee drug for the global insulin market, which is projected to break the $90 billion threshold by 2029.

rBIO says it recently completed testing of the properties of R-biolin, an insulin drug that’s biologically identical to Novo Nordisk’s Novolin drug. The patent for Novolin about two decades ago. In March 2023, the Dutch drugmaker announced it was slashing the list price of Novolin by 65 percent to $48.20 per vial and $91.09 per FlexPen.

Executives at rBIO are now pursuing a partnership with a contract research organization to manage clinical trials of R-biolin. If those trials go well, R-biolin will seek approval to supply its insulin therapy to diabetes patients around the world.

Washington University in St. Louis is rBIO’s academic partner for the R-biolin project.

The rBIO platform produces insulin at greater yields that traditional manufacturing techniques do. The company is striving to drive down the cost of insulin by 30 percent.

About 38 million Americans have diabetes, with the vast majority being treated for type 2 diabetes, according to the U.S. Centers for Disease Control and Prevention (CDC). Many people with diabetes must take insulin to control their blood sugar levels.

Research company iHealthcareAnalyst predicts the global market for insulin will surpass the $90 billion mark in 2029.

“There has been a lot of talk in the media about reducing the cost of insulin for diabetic patients, but what is often overlooked is that the domestic demand for insulin will soon outpace the supply, leading to a new host of issues,” Cameron Owen, co-founder and CEO of rBIO, says in a news release.

“We’re dedicated to addressing the growing demand for accessible insulin therapies, and … we’re thrilled to announce the viability of our highly scalable manufacturing process.”

Professionals from the University of California San Diego and Johns Hopkins University established rBIO in 2020. The startup moved its headquarters from San Diego to Houston in 2022.

CEO Cameron Owen and Chief Scientific Officer Deenadayalan Bakthavatsalam work on insulin purification in the Houston lab. Photo courtesy

This week's roundup of Houston innovators includes Gaurab Chakrabarti of Solugen, Sandy Guitar of HX Venture Fund, and Cameron Owen of rBIO. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from synthetic biology to venture capital — recently making headlines in Houston innovation.

Gaurab Chakrabarti, the CEO and co-founder of Solugen

Gaurab Chakrabarti shared his entrepreneurial journey on the SXSW stage this year. Photo courtesy of the Greater Houston Partnership

Houston doesn't have too many unicorns — startups valued at $1 billion or more — in its innovation ecosystem, but Solugen, a sustainable chemicals company, is among the elite group. Gaurab Chakrabarti, the CEO and co-founder of the company, joined Houston House by the Greater Houston Partnership, to share his story on the SXSW stage.

“You do make your own luck, but you have to be putting in the work to do it," Chakrabarti says, adding that it's not an easy thing to accomplish. “There are things you can be doing to increase your luck surface area."

He shared several lessons he learned on his founder journey in the discussion. Read more.

Sandy Guitar, managing director of HX Venture Fund

Sandy Guitar shares some lessons learned from the fallout of Silicon Valley Bank. Photo via HXVF

Following the failure of Silicon Valley Bank, there's one thing Sandy Guitar can say has changed for Houston innovators: Bank diversification is going to be a must.

“We didn't think we needed one last week, but this week we know we need a resilience plan," she says, explaining that bank diversification is going to be added to "the operational due diligence playbook." Read more.

Cameron Owen, co-founder and CEO of rBIO

San Diego-based rBIO moved to Houston to take advantage of the growing ecosystem of biomanufacturing and synthetic biology. Photo courtesy of rBIO

Founded in San Diego, rBIO recently relocated to Houston and has big plans for settling in the city, says Cameron Owen, the company's co-founder and CEO.

“Companies from California like us and the coastal areas were converging here in Houston and creating this new type of bioeconomy,” he tells InnovationMap.

He shares that Houston wasn't originally on his radar, until it was. A visit turned into a relocation, and it's just the beginning for the biotech startup that's focused on using synthetic biology for pharmaceuticals. Read more.

San Diego-based rBIO moved to Houston to take advantage of the growing ecosystem of biomanufacturing and synthetic biology. Photo via Getty Images

California-founded biotech startup relocates to join Houston's emerging bioeconomy

new to hou

Cameron Owen had an idea for a synthetic biology application, and he pitched it to a handful of postdoctoral programs. When he received the feedback that he didn't have enough research experience, he decided to launch a startup based in San Diego around his idea. He figured that he'd either get the experience he needed to re-apply, or he'd create a viable company.

After three years of research and development, Owen's path seems to have taken him down the latter of those two options, and he moved his viable company, rBIO, to Houston — a twist he didn't see coming.

“Houston was not on my radar until about a year and a half ago,” Owen says, explaining that he thought of Houston as a leading health care hub, but the coasts still had an edge when it came to what he was doing. “San Diego and the Boston area are the two big biotech and life science hubs.”

But when he visited the Bayou City in December of 2021, he says he saw first hand that something new was happening.

“Companies from California like us and the coastal areas were converging here in Houston and creating this new type of bioeconomy,” he tells InnovationMap.

Owen moved to Houston last year, but rBIO still has an academic partner in Washington University in St. Louis and a clinical research organization it's working with too, so he admits rBIO's local footprint is relatively small — but not for long.

"When we look to want to get into manufacturing, we definitely want to build something here in Houston," he says. "We’re just not to that point as a company."

In terms of the stage rBIO is in now, Owen says the company is coming out of R&D and into clinical studies. He says rBIO has plans to fundraise and is meeting with potential partners that will help his company scale and build out a facility.

With the help of its CRO partner, rBIO has two ongoing clinical projects — with a third coming next month. Owen says right now rBIO is targeting the pharmaceutical industry’s biologics sector — these are drugs our bodies make naturally, like insulin. About 12 percent of the population in the United States has diabetes, which translates to almost 40 million people. The demand for insulin is high, and rBIO has a way to create it — and at 30 percent less cost.

This is just the tip of the iceberg — the world of synthetic biology application is endless.

“Now that we can design and manipulate biology in ways we’ve never been able to before,” Owen says, "we’re really only limited by our own imagination.”

Synthetic biology is a field of science that involves programing biology to create and redesign natural elements. While it sounds like science fiction, Owen compares it to any other type of technology.

“Biology really is a type of software,” he says. “Phones and computers at their core run on 1s and 0s. In biology, it’s kind of the same thing, but instead of two letters, it’s four — A, C, T, and G.”

“The cool thing about biology is the software builds the hardware,” he continues. “You put that code in there and the biology builds in and of itself.”

Owen says the industry of synthetic biology has been rising in popularity for years, but the technology has only recently caught up.

“We’re exploring a brave new world — there’s no doubt about that,” Owen says.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston e-commerce giant Cart.com launches government-focused subsidiary

government branch

Houston e-commerce and logistics unicorn Cart.com has launched a new subsidiary.

Cart Government Solutions (CGS), which was announced earlier this week, will provide supply chain and logistics services and software for the federal and state government sectors. The new subsidiary will be headquartered in Washington, D.C., and operate out of about 6 million square feet of secure warehouse space across 14 U.S. facilities, according to a news release from Cart.com. It will support both domestic and overseas logistics.

Industry veteran Gregg Zegras will lead the new entity as president. Zegras previously served as Cart.com's chief revenue officer, according to LinkedIn. Before that, he served as president of Connecticut-based Pitney Bowes Global eCommerce, a digital shipping solutions company.

Remington Tonar, Cart.com's co-founder, will serve as CGS's chief innovation officer.

“Government agencies face procurement and logistics challenges that many commercial platforms simply weren’t built to solve,” Zegras said in the news release. “Cart Government Solutions exists to change that. We’re combining the speed and innovation of a technology company with the compliance rigor, security, and operational depth that federal and state customers require, and we’re doing it with a team that has spent careers working alongside and inside these agencies.”

According to the company, CGS will focus on meeting compliance and security requirements in the public sector. Some of the services the new entity will offer include:

Inventory management
Cold-chain and specialty storage for pharmaceuticals, medical devices and regulated goods
Enterprise-grade supply chain software
Government-compliant webstores and online ordering portals
Cybersecurity operations

Cart.com has been serving the public sector since 2022, when the company began distributing COVID-19 health supplies nationwide, according to the news release. Through that pandemic-era contract, the company reports it moved more than 725 million units, with an average of under two days per shipment.

Cart.com was founded in Houston in 2020, though it briefly moved its headquarters to Austin. The company reached unicorn status with its $60 million Series C raise in 2023. It most recently raised $180 million in growth capital from private equity firm Springcoast Partners in March, which put the startup over the $1 billion in fundraising mark in just six years.

At the time, Cart.com said it planned to scale its logistics network, expand AI capabilities and develop workflow automation tools.

Houston-based KBR Inc. also recently launched a government services spinoff. Read more here.

2 Houston universities named best colleges of 2027 by Princeton Review

A-Plus Ratings

Back-to-school season is has returned in full force, and that means it's time for college rankings. Two Houston universities in particular are being hailed as the top of the class for 2027.

The high caliber schools — Rice University and University of Houston — earned new acclaim in The Princeton Review's ranking of the "Best 392 Colleges" for 2027.

The Princeton Review's 35th annual "Best Colleges" rankings are determined by a survey of 172,000 current college students that gave "candid feedback" about their schools and their experiences. The flagship guide does not rank the schools overall, but it does rank them across 50 different categories, including best-run colleges, best quality of life, happiest students, best athletic facilities, among others.

In all, 14 Texas institutions were highlighted in the overall list of the 392 best colleges.

Schools don't pay to be included in the guide, but The Princeton Review clarified that schools could pay for a "featured" designation. No Houston university paid to be featured in this year's guide. Trinity University in San Antonio and Southwestern University, a private school in the Austin suburb Georgetown, were the only two Texas schools that paid to be "featured."

Rice and UH have been on a winning streak in separate reports of the best universities worldwide, best graduate schools, and best online degree programs.

In addition to being included in the overall list, Rice was highlighted as one of the Best Value Colleges, Colleges That Create Futures, and it earned high marks in Princeton Review's Mental Health Honor Roll 2026. The home of the Rice Owls also starred in the regional Best Southwest list that contained 41 universities across Arizona, Colorado, New Mexico, Oklahoma, and Texas.

"Rice University stands out as a leading research university where academic diversity and a wide array of interdisciplinary institutes and centers make it easy for students to explore multiple areas of interest," the school's profile says. "At Rice, 'knowledge isn’t siloed — students are constantly crossing disciplines and interests in ways that feel natural rather than exceptional.'"

Rice earned the following rankings on 14 other lists:

No. 1 – Lots of Race/Class Interaction
No. 3 – Best College Newspaper
No. 9 – Friendliest Students
No. 11 – Best Quality of Life
No. 13 – Great Financial Aid
No. 14 – Top 50 Best Value Private Colleges
No. 17 – Their Students Love These Colleges
No. 18 – Top 20 Best Value Private Colleges Without Aid
No. 18 – Best Student Support and Counseling Services
No. 19 – Best College Dorms
No. 21 – Students Study the Most
No. 24 – Best Campus Food
No. 24 – Best College Radio Station
No. 24 – Best-Run colleges

The University of Houston also appeared in the Best Southwest, Best Value Colleges, and Colleges That Create Futures lists, and it was named a top Green College, which examined schools that "share superb sustainability practices, a strong foundation in sustainability education, and a healthy quality of life for students on campus

UH earned five more accolades:

No. 1 – Top 50 Undergraduate Schools for Entrepreneurship Studies
No. 1 – Top Undergraduate Schools for Entrepreneurship Studies in the Southwest
No. 8 – Most Politically Moderate Students
No. 15 – Financial Aid Not So Great
No. 42 – Top 50 Best Value Public Colleges

In the school's profile, students say they had an overall positive experience thanks to UH's excellent academic offerings and dedicated faculty members.

"Students confirm that 'the research and other academic opportunities... are very accessible to students who seek it out,'" the profile says. "This includes taking advantage of UH’s vast alumni network (more than 325,000 and counting), not to mention its location in the corporate center of Houston, where 'the opportunities that are provided are immense.'"

The 12 other public and private universities in Texas included in The Princeton Review's 2027 guide are:

The University of Texas at Austin
Southwestern University, Georgetown
Baylor University, Waco
Texas A&M University - College Station
Trinity University, San Antonio
Texas State University, San Marcos
Angelo State University, San Angelo
Texas Christian University, Fort Worth
University of Dallas, Irving
Southern Methodist University, Dallas
The University of Texas at Dallas, Richardson
Austin College, Sherman

---

A version of this story originally appeared on CultureMap.com.

Houston named the No.1 emerging city for biopharma in inaugural report

Biopharma Leader

Houston is ranked No.1 on the first-ever Next 10 U.S. Biopharma Clusters report published by Genetic Engineering & Biotechnology News (GEN).

The report, which ranks the best emerging hubs for life science activities, considered patents, NIH funding, lab space, venture capital investments, and the number of jobs in regions in cities, states and “clusters” across the U.S. GEN touts Houston as the top city for the biopharma industry due to a surge in funding, job creation, medical innovations and startup success.

Here’s how Houston ranked in the report’s different categories;

No. 1 for NIH funding with 2,262 awards totaling more than $1.25 billion
No. 2 for emerging regions for jobs, with 28,000 jobs
No. 2 for lab space, with roughly 8 million square feet in the market
No. 6 for patents, with 2,760 patent families

According to BioHouston chairman Jeff Wade, Houston secured half a billion dollars in venture capital funding in 2025 and 2026 to date.

The report called out major biopharm news out of Houston in the last few months, including Bristol Myers Squibb selecting Houston for its $1 billion, 600,000-square-foot manufacturing site and Eli Lily selecting Houston for its $6.5 billion, 236-acre manufacturing site. Both facilities will be located within Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston.

Houston startups like CrossBridge Bio and Duracyte were also mentioned in the report. CrossBridge, which develops antibody-drug conjugates for cancer, was acquired by Eli Lily in April for $300 million. Duracyte, a “living pharmacy” company, was launched out of Rice University’s biotech venture studio RBL LLC this spring and is backed by up to a $45 million Advanced Research Projects Agency for Health (ARPA-H) award.

The startup is working to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time.

“There’s a lot of great talent, but the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights,” Omid Veiseh, Duracyte co-founder and managing partner of RBL LLC, told GEN. “There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”

The report also touted Houston’s Texas Medical Center, home to the University of Texas MD Anderson Cancer Center and Baylor College of Medicine, and international partnerships like the recently expanded TMC Korea BioBridge.

Other cities to make the list include:

No. 2 Minneapolis-St. Paul
No. 3 Denver-Boulder
No. 4 St. Louis
No. 5 Dallas-Fort Worth

States to make the list include:

No. 1 Ohio (including Cincinnati, Cleveland, and Columbus)
No. 2 Indiana (including Indianapolis)
No. 3 Florida (including Jacksonville and Miami-Fort Lauderdale)
No. 4 Georgia (including Atlanta and Augusta)
No. 5 Wisconsin (including Madison and Kenosha)

Regional state clusters to watch include:

Phoenix
Pittsburgh
Greater Richmond, Virginia
South Carolina
Utah

See the full report here.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME